Producer
Sun Pharmaceutical Industries
5
Inputs supplied
3
Goods downstream
1
Facilities
0
Stories
What they make
5 inputs Sun Pharmaceutical Industries supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Sun Pharmaceutical Industries makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
US Business
30%India Branded Generics
33%Emerging Markets and Rest of World
28%Global API
9%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2014
Sun Pharmaceutical manufactures APIs across therapeutic areas with zero visible connection to each other: buprenorphine (opioid addiction treatment), tretinoin (acne/anti-aging dermatology), corticosteroids (eczema/psoriasis), and cyclosporine A (dry eye disease and organ transplant). These are used by different patient populations, prescribed by different specialists, and sold through different channels. When Sun Pharma's Halol facility received an FDA Warning Letter in 2014, the resulting production uncertainty created shortages across all of these drug classes simultaneously — demonstrating how Indian pharmaceutical consolidation creates correlated supply chain failures that the US healthcare system was not designed to anticipate.
U.S. Food & Drug Administration ↗Capacity2024
Sun Pharmaceutical controls 56% of the global buprenorphine API export market — making it the single largest upstream supplier of the drug that over 3 million Americans take daily for opioid use disorder treatment. Sun manufactures buprenorphine at API facilities in Gujarat, India, converting thebaine sourced primarily from Australia into bulk buprenorphine API shipped to finished-dose manufacturers globally. The US buprenorphine supply chain runs: Tasmania (Extractas) → thebaine → Gujarat (Sun Pharma) → buprenorphine API → US formulators → Suboxone/Sublocade/generic strips → patient. Sun Pharma FY2024 Annual Report; DEA aggregate production quota data.
Sun Pharmaceutical Industries ↗Origin2024
Sun Pharmaceutical was founded in 1983 by Dilip Shanghvi with a ₹10,000 investment and 5 psychiatry products sold to doctors in Bihar and Rajasthan. Forty years later it is India's most valuable pharmaceutical company (~$45B market cap) and the world's fifth-largest specialty generics company by revenue. The growth path was almost entirely acquisitive: 40+ acquisitions including DUSA Pharmaceuticals (US specialty dermatology, 2012), Taro Pharmaceutical (Israeli topicals, hostile takeover 2007-2010), URL Pharma (US generics, 2012), and Ranbaxy Laboratories ($3.2B, 2014 — India's formerly largest generic pharma, then under US federal criminal plea for drug safety violations). Shanghvi is India's third-wealthiest individual, and Sun Pharma's Ranbaxy integration remains one of the largest and most complex pharma acquisitions in emerging market history.
Sun Pharmaceutical Industries ↗